Traditional drug delivery vectors exhibit physicochemical characteristics that limit their ability to pass through biological barriers, in particular the blood-brain barrier, to reach the brain, which is the main target of the polyQ disease therapeutics. To improve the brain bioavailability of therapeutic active agents, new formulations based on nanocarriers have emerged.